아시네토박터 폐렴 치료제 시장 규모, 점유율, 동향 분석 리포트 : 약제 클래스별, 투여 경로별, 지역별, 부문별 예측(2024-2030년)

Acinetobacter Pneumonia Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Xacduro, Polymyxins, Cephalosporins, Carbapenems), By Route Of Administration (Oral, Parenteral), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,590,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,034,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,922,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

아시네토박터 폐렴 치료제 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 아시네토박터 폐렴 치료제 시장 규모는 2024-2030년에 6.70%의 CAGR을 기록하며, 2030년까지 4억 7,096만 달러에 달할 전망입니다.

아시네토박터 감염의 높은 발생률, 항생제 내성 증가, 광범위한 조사 개발, 유리한 정부 구상 및 자금 지원, 약물 내성 증가 등 여러 가지 요인이 시장 성장을 가속하는 요인으로 작용하고 있습니다. 병원내 감염을 유발하는 주요 병원균입니다. 이 병원균은 인공호흡기 관련 폐렴과 혈류 감염을 유발합니다. 이 균주는 다제내성균으로 보고되고 있으며, 매우 빠르게 확산될 수 있습니다.

이 미생물의 치료는 어렵고 Acinetobacter baumannii의 다제 내성으로 인해 어려움을 겪고 있습니다. 병용 요법은 이러한 유형의 감염에 가장 널리 사용되는 치료법입니다. 아시네토박터 폐렴 치료의 1차 선택 약물에는 B-락탐계 항생제, 세팔로스포린계 항생제, 카바페넴계 항생제, 플루오로퀴놀론계 항생제, 설박탐계 항생제, 설폰아미드계 항생제 등이 있습니다. 이들 치료제는 중증도에 따라 단독 또는 병용 요법의 일부로 사용됩니다. 1차 약물이 효과가 없는 경우, 2차 약제로 아미노글리코사이드계, 폴리믹신계, 테트라사이클린계, 글리실사이클린계 등의 항생제를 투여합니다. 이들 약제는 부작용 때문에 2차 선택약으로 분류됩니다.

아시네토박터 폐렴 치료제 시장 보고서 하이라이트

• 세팔로스포린 계열 약물은 2023년 가장 큰 매출 점유율을 차지할 것으로 예상됩니다. 세프타디짐은 1차 선택 약물로, 세피데로콜은 2차 선택 약물로 사용됩니다.
• 또한 설박탐 부문에서는 새로 출시된 자쿠듀로가 예측 기간 중 높은 CAGR로 성장할 것으로 예상됩니다.
• 투여 경로에 따라 비경구 투여 부문은 2023년 가장 큰 매출 점유율을 차지했습니다. 정맥 투여를 통한 항생제의 신속하고 직접적인 전달은 빠른 흡수와 효능을 보장하여 심각한 감염성 질환을 치료하는 데 선호되는 방법입니다.
• 자쿠듀로(주사용 설박탐, 주사용 듀로박탐), 폴리믹신(콜리스틴), 카바페넴, 아미노글리코사이드는 아시네토박터 폐렴을 치료하기 위해 비경구적으로 투여되는 약제 중 일부입니다.
• 2023년에는 북미가 37.31%의 점유율을 차지했습니다. 이는 높은 의료 인프라, 높은 인지도, 임상시험을 위한 광범위한 조사 활동으로 인한 것입니다.
• 이 지역은 아시네토박터 폐렴의 유병률이 높고, 질병 진단과 치료에 대한 인식도 높습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 아시네토박터 폐렴 치료제 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 모시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 촉진요인 분석
  • 시장 억제요인 분석
• 아시네토박터 폐렴 치료제 시장 분석 툴
  • 업계 분석 - Porter의 산업 분석
  • PESTEL 분석
  • 가격 분석
  • 파이프라인 분석

제4장 아시네토박터 폐렴 치료제 시장 : 약제 클래스 추정·동향 분석

• 세계의 아시네토박터 폐렴 치료제 시장 : 약제 클래스 부문 대시보드
• 세계의 아시네토박터 폐렴 치료제 시장 : 약제 클래스 변동 분석
• 세계의 아시네토박터 폐렴 치료제 시장 규모와 동향 분석, 약제 클래스별, 2018-2030년
• 세팔로스포린
• 플루오로퀴놀론
• Glycylcycline
• 카바페넴
• β-락탐계 항생제
• Sulbactam
• 아미노글리코시드
• 폴리믹신
• 테트라사이클린
• 술폰아미드
• 기타

제5장 아시네토박터 폐렴 치료제 시장 : 투여 경로 추정·동향 분석

• 세계의 아시네토박터 폐렴 치료제 시장 : 투여 경로 부문 대시보드
• 세계의 아시네토박터 폐렴 치료제 시장 : 투여 경로 변동 분석
• 세계의 아시네토박터 폐렴 치료제 시장 규모와 동향 분석, 투여 경로별, 2018-2030년
• 비경구
• 오랄
• 기타

제6장 아시네토박터 폐렴 치료제 시장 : 지역 추정·동향 분석

• 지역의 시장 대시보드
• 시장 규모·예측, 동향 분석, 2018-2030년
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제7장 경쟁 구도

• 주요 시장 참여 기업에 의한 최근 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 구도
  • Pfizer Inc.
  • Merck &Co., Inc.
  • GlaxoSmithKline plc(GSK)
  • AstraZeneca plc
  • Novartis AG
  • Johnson &Johnson
  • Sanofi SA
  • Bayer AG
  • Basilea Pharmaceutica

KSA

영문 목차

영문목차

Acinetobacter Pneumonia Therapeutics Market Growth & Trends:

The global acinetobacter pneumonia therapeutics market size is expected to reach USD 470.96 million by 2030, registering a CAGR of 6.70% from 2024 to 2030, according to a new report by Grand View Research, Inc. Several factors are responsible for driving market growth including a high incidence of acinetobacter infections, rising antibiotic resistance, extensive R&D, and favorable government initiatives & funding, and rising drug resistance. Acinetobacter baumannii is a major pathogen responsible for causing hospital-acquired infections in hospitalized patients. The pathogen causes ventilator-associated pneumonia and bloodstream infection. This strain of microorganisms has been reported to be multidrug-resistant and can spread extremely fast.

The treatment of this microorganism can be challenging and is hampered due to the multidrug resistance of the Acinetobacter baumannii. Combination therapy is the most widely used treatment for these kinds of infections. The first line of treatment for acinetobacter pneumonia includes drug classes, such as B-lactam antibiotics, cephalosporins, carbapenem, fluoroquinolone, sulbactam, and sulfonamide. The therapeutics are used in monotherapy or as part of combination therapy depending on the severity of illness. In case the first-line treatment is not effective, second-line antibiotics are administered, which include drug classes, such as aminoglycoside, polymyxins, tetracycline, and glycylcycline. These drugs are considered second-line due to their adverse effects.

Acinetobacter Pneumonia Therapeutics Market Report Highlights:

• The cephalosporins drug class segment accounted for the largest revenue share in 2023. Ceftazidime is used as a first-line treatment; cefiderocol is used as second-linene treatment for the disease
• In addition, the newly launched Xacduro under the sulbactam segment is expected to grow at a significant CAGR during the forecast period
• Based on the route of administration, the parenteral segment accounted for the largest revenue share in 2023. The rapid and direct delivery of antibiotics via the IV route ensures rapid absorption and efficacy and makes it the preferred method for treating severe infections
• Xacduro (sulbactam for injection; durlobactam for injection), polymyxins (colistin), carbapenems, and aminoglycosides are some of the drugs administered parenterally for the treatment of acinetobacter pneumonia
• In 2023, North America dominated with a share of 37.31% owing to the advanced healthcare infrastructure, high awareness levels, and extensive research activities for clinical trials
• The region has a high prevalence of acinetobacter pneumonia along with high awareness about disease diagnosis and treatment

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Route of Administration
• 1.3. Regional scope
• 1.4. Estimates and forecasts timeline
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased database
  • 1.6.2. GVR's internal database
  • 1.6.3. Secondary sources
  • 1.6.4. Primary research
  • 1.6.5. Details of primary research
    • 1.6.5.1. Data for primary interviews in North America
    • 1.6.5.2. Data for primary interviews in Europe
    • 1.6.5.3. Data for primary interviews in Asia Pacific
    • 1.6.5.4. Data for primary interviews in Latin America
    • 1.6.5.5. Data for Primary interviews in MEA
• 1.7. Information or Data Analysis
  • 1.7.1. Data analysis models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity flow analysis (Model 1)
  • 1.9.2. Approach 1: Commodity flow approach
  • 1.9.3. Volume price analysis (Model 2)
  • 1.9.4. Approach 2: Volume price analysis
• 1.10. List of Secondary Sources
• 1.11. List of Primary Sources
• 1.12. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug class outlook
  • 2.2.2. Route of administration outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Acinetobacter Pneumonia Therapeutics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing incidence of Acinetobacter infections
    • 3.2.1.2. Increasing prevalence of antibiotic resistance
    • 3.2.1.3. Increasing research & development and fundings
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Side effects and adverse reactions
    • 3.2.2.2. High cost of drug development
• 3.3. Acinetobacter Pneumonia Therapeutics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis
  • 3.3.4. Pipeline Analysis

Chapter 4. Acinetobacter Pneumonia Therapeutics Market: Drug Class Estimates & Trend Analysis

• 4.1. Global Acinetobacter Pneumonia Therapeutics Market: Drug Class Segment Dashboard
• 4.2. Global Acinetobacter Pneumonia Therapeutics Market: Drug Class Movement Analysis
• 4.3. Global Acinetobacter Pneumonia Therapeutics Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 4.4. Cephalosporins
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Fluoroquinolone
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Glycylcycline
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Carbapenem
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. B-Lactam antibiotics
  • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Sulbactam
  • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Aminoglycoside
  • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.11. Polymyxins
  • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.12. Tetracycline
  • 4.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.13. Sulfonamide
  • 4.13.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.14. Other
  • 4.14.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Acinetobacter Pneumonia Therapeutics Market: Route of Administration Estimates & Trend Analysis

• 5.1. Global Acinetobacter Pneumonia Therapeutics Market: Route of Administration Segment Dashboard
• 5.2. Global Acinetobacter Pneumonia Therapeutics Market: Route of Administration Movement Analysis
• 5.3. Global Acinetobacter Pneumonia Therapeutics Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 5.4. Parenteral
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Oral
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Other
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Acinetobacter Pneumonia Therapeutics Market: Regional Estimates & Trend Analysis by

• 6.1. Regional Market Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Mexico
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2023
  • 7.3.4. Pfizer Inc.
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Merck & Co., Inc.
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. GlaxoSmithKline plc (GSK)
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. AstraZeneca plc
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Novartis AG
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Johnson & Johnson
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Sanofi S.A.
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Bayer AG
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Basilea Pharmaceutica
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives

관련자료